Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Methylphenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide is an experimental small molecule compound with the chemical formula C22H34N4O2 and a molecular weight of approximately 386.54 g/mol[1][3][6]. It belongs to the class of dipeptides, specifically containing a sequence of two amino acids, and features a prolinamide moiety. The compound has not been approved for any indication and there are no reported clinical trials beyond preclinical or biochemical testing phases[1][6]. Its mechanism of action, pharmacological activity, therapeutic target(s), and potential indications have not been described in publicly available sources as of June 2025.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-Methylphenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide.